Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
Vascular endothelial growth factor (VEGF) is essential in the pathogenesis of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). As such, VEGF inhibitors have become commonly used and effective pharmacologic strategies for both diseases. However, limitations exist, such as co-payments and the need for in-person clinical visits and multiple intravitreal injections each year. New therapies are emerging to address these limitations by improving the durability of treatment response to decrease treatment burden.
In this program, expert faculty discuss the role of VEGF in the pathogenesis of nAMD and DME, review recent clinical trial data for VEGF inhibitors, and examine the potential of novel therapies as future treatment options.
This educational activity is an archive of the live virtual symposium held on July 31, 2025.
Target Audience
This educational activity is directed toward retina specialists and comprehensive ophthalmologists who would be involved in the management of patients with neovascular retinal diseases such as nAMD and DME who might be treated with VEGF inhibitors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the role of VEGF in the pathogenesis of nAMD and DME
- Describe the mechanism of action of novel therapies that target VEGF
- Assess current evidence evaluating the role of VEGF inhibitors in the treatment of nAMD and DME
- Identify patients appropriate for treatment with VEGF inhibitors based on clinical presentation and goals of therapy
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here